Optimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing
- 1 October 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (10) , 3760-3762
- https://doi.org/10.1128/aac.00488-07
Abstract
Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.Keywords
This publication has 12 references indexed in Scilit:
- Pathogenesis ofAspergillus fumigatusand the Kinetics of Galactomannan in an In Vitro Model of Early Invasive Pulmonary Aspergillosis: Implications for Antifungal TherapyThe Journal of Infectious Diseases, 2007
- Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine againstCandida albicansand Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal EffectAntimicrobial Agents and Chemotherapy, 2006
- Pharmacodynamic Activity of Amphotericin B Deoxycholate Is Associated with Peak Plasma Concentrations in a Neutropenic Murine Model of Invasive Pulmonary AspergillosisAntimicrobial Agents and Chemotherapy, 2006
- Surface Response Modeling to Examine the Combination of Amphotericin B Deoxycholate and 5‐Fluorocytosine for Treatment of Invasive CandidiasisThe Journal of Infectious Diseases, 2005
- Application of an In Vitro Infection Model and Simulation for Reevaluation of Fluoroquinolone Breakpoints for Salmonella enterica Serotype TyphiAntimicrobial Agents and Chemotherapy, 2005
- Model appropriateness and population pharmacokinetic modeling.2003
- In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing MethodsAntimicrobial Agents and Chemotherapy, 2002
- Pharmacodynamics of Amphotericin B in a Neutropenic-Mouse Disseminated-Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2001
- In Vivo Characterization of the Pharmacodynamics of Flucytosine in a Neutropenic Murine Disseminated Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2000
- Evolving Role of Flucytosine in Immunocompromised Patients: New Insights into Safety, Pharmacokinetics, and Antifungal TherapyClinical Infectious Diseases, 1992